Law Firm Reminds Unicycive Therapeutics Shareholders of Lawsuit Lead Plaintiff Deadline

Levi & Korsinsky, LLP has notified investors in Unicycive Therapeutics, Inc. (NASDAQ: UNCY) that a securities class action lawsuit has been filed on behalf of shareholders who purchased securities between December 29, 2025, and June 29, 2026.

The lawsuit alleges that Unicycive failed to adequately disclose deficiencies at a third-party manufacturing facility, which led to a second Complete Response Letter from the U.S. Food and Drug Administration (FDA). This resulted in a 39.1% single-day stock price decline.

Levi & Korsinsky reminds investors that the deadline to apply for lead plaintiff appointment in the case is November 2, 2026. The firm is seeking investors who purchased UNCY securities during the class period and suffered losses.

While Unicycive's annual report indicated the FDA could request supplemental information, the complaint claims the company did not inspect the manufacturer's facility or audit its compliance with current good manufacturing practices prior to resubmission. The lawsuit asserts that management's characterization of "significant progress" towards FDA compliance was based on discussions rather than verified inspection results.

Following the FDA's issuance of a second Complete Response Letter in June 2026, citing the same manufacturing deficiencies, Unicycive's stock price fell sharply. The law firm argues that generic risk factor language cannot substitute for disclosing specific, known problems impacting a company's operations.